matt mindset tabl turn hard find go
well day given organ revenu growth near top
end group revenue/product momentum head
ceo mile white normal worst critic struggl point area
improv sore need call nutrit one weak spot growth
improv y/i sequenti biggest challeng stage
execut well opportun scale new product continu integr stj
alr keep invest sustain growth comp get
tougher said still think stock offer good valu growth
think initi guidanc conserv view libr epd cardio
could drive upsid consensu rais number mainli fx libr
epd increas pt base new ep
prior target base prior ep expect
grow revenu consist high end msd rang
underli basi given strong oper execut new product flow
top pick rate share overweight think consist revenu
growth near high end larg cap med-tech group help drive multipl
expans move share higher
year begin roll-out key product could drive
growth launch freestyl libr us novemb medicar approv
decemb rx growth robust gate see libr mass
market product ad libr patient quarter reflect
limit contribut us stage divis get boost
recent launch confirm rx icm mri safe crt-d icd recent
launch xienc sierra product ce mark countri help drive
vascular revenu growth continu launch alin platform
us continu throughout year guidanc msd dx revenu
growth msd-hsd growth impli acceler
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view abbott high qualiti
asset attract outlook good busi
exposur leverag lt growth emerg
market strong manag view stock
under-valued think trade premium
group time view stj strengthen
medic devic footprint could improv
growth area
upsid case depend sever key factor
stabil emerg market revenu upsid
nutrit diagnost oper
out-performance margin initi smooth
integr stj deal upsid stj growth
synergi assumpt
downsid driven slowdown emerg
market growth share loss price pressur
nutrit share loss vascular fx
worsen integr challeng stj
includ revenu compar
oper vs consensu ep vs consensu guidanc
beat consensu expect diagnost medic devic
establish pharma come in-lin nutrit divis importantli
comp adjust growth acceler dx devic pharma devic
divis stood us inflect diabet growth libr improv
mri-saf devic better result ep cathet heart failur
continu strong growth neuro structur heart view impress
result sign momentum head
gave guidanc includ ep rang
street midpoint guidanc exce prior street estim view
conserv given underli momentum busi addit boost
could get deal accret stj alr fx expect
organ growth contribut diagnost organ
growth exclud favour fx impact top-lin slightli less
guid gm revenu sg somewhat revenu
invest revenu result tax reform expect tax rate
year also note paid debt jan
plan continu pay debt year larg acquisit radar
expect adjust ep consensu
guid organ growth quarter contribut
rapid diagnost organ growth exclud posit fx impact
strengen eurooper baselin ex alr divestituresa nutrit ex-fxlsdb establish pharma ex-fxhsdc diagnost ex-fxm-hsdalin launch drive growth medic devic ex-fxm-hsddiabet ex-fxdd growthlibr growth good estimate gross pension incom reclass cog sg non-oper incomesg aa bit reclass increment interest debt repaid jan addit repaymentnon-oper mminclud pension changesoth mmgain hedgingtot interest otherbelow debt/ebitda year end net tax reformpro-forma share mid barclay abbott laboratori
top-lin gm expect somewhat revenu sg
expect revenu expect sale
improv growth dx driven alin
guid dx growth msd msd-hsd full year
growth expect acceler driven larg on-going launch
continu uptak alin alin platform includ differ system
support growth across diagnost busi core lab transfus point-
of-car hematolog molecular diagnost system approv
europ approv us come remaind
year emphas launch system highli scalabl
materi impact growth time reason growth ramp start slow
sale cycl addit approv etc gather momentum launch
continu aler comment integr gone well quickli
ahead schedul liter everyth
comment expect surpris peopl diabet categori strong
growth rate ad custom quarter doesnt reflect
signific contribut us yet compani invest heavili
expans comment libr revenu number
reason emphas well ramp go overal highlight
libr mass market product broad appeal type type diabet
remind fda approv abt freestyl libr flash glucos monitor
first continu glucos monitor system cgm use adult make
treatment decis without calibr fingerstick note titl
libr fda approv could pressur share publish
 nutrit ex-fxlsdb establish pharma ex-fxhsdc diagnost medic devicesm-hsd combin vascular stjdiabet ex-fxdd growthstrong market uptak freestyl libreep sturcut heart hf neurostrong market uptak freestyl librerhythm management vascularstrong market uptak freestyl libregross interest barclay abbott laboratori
segment result dx devic epd come in-
line nutrit
ww nutrit sale vs consensu increas xfx vs lsd
guidanc adult nutrit revenu increas xfx driven strong sale
ww ensur glucerna pediatr nutrit revenu xfx us
pediatr nutrit revenu growth driven strong sale pediasur pedialyt
us ou growth declin slightli due continu market challeng china
diagnost sale vs consensu grew xfx vs msd
guidanc lab revenu grew point revenu
increas xfx lab revenu growth driven market share gain
ww note launch alin system us expect point
revenu growth driven continu uptak i-stat handheld system molecular
segment revenu increas xfx reflect growth infecti diseas
test sale off-set on-going scale mostli us test rapid diagnost
acquisit aler gener revenu driven flu strep test
infecti diseas test
establish sale vs consensu grew
xfx driven key emerg market includ brazil russia india china
import market grew xfx growth driven larg double-
digit growth key geographi includ china india latam revenu increas
due time sale certain geographi
medic devic revenu vs consensu increas xfx
cardiovascular neuromod grew oper basi driven doubl digit
growth ep heart failur structur heart neuromod ep revenu growth driven
launch confirm rx insert cardiac monitor icm structur heart
revenu growth driven continu uptak mitraclip note continu
growth use heartmat approv contribut growth
neuromod doubl digit revenu growth driven new product design treat
chronic pain movement disord rhythm manag benefit key fda
approv includ mri label quadra assura quadra assura mp fortifi
assura vascular receiv ce mark xienc sierra de diabet
care revenu grew xfx driven doubl digit intern revenu
growth led freestyl libr remind libr approv us
receiv coverag
revenu mm
ep
abbott laboratori consensusy/yxfxtot mm except ep actualbarclay consensusabbott laboratori excl incom excl tax dilut mm except ep actualbarclay consensu barclay abbott laboratori
compani report barclay research
last updat mm except year end dec growth growth growth profit revenu sg inc med-tech incom expens incom tax incom pro-forma average share increas ep cont increas barclay abbott laboratori
matthew taylor cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
